

Review Paper:

***Bacopa monnieri* as a Potential Natural Acetylcholinesterase Inhibitor for Neurodegenerative Disease Management**

Khan Amanulla

Anjuman Islam Janjira Degree College of Science, Murud-Janjira, Maharashtra, INDIA
dramanullak@gmail.com**Abstract**

Neurodegenerative disorders including Alzheimer's disease (AD) and Parkinson's disease (PD), present major global health challenges due to their progressive pathology and limited therapeutic interventions. Acetylcholinesterase (AChE) inhibitors are commonly prescribed to mitigate cognitive decline; however, their long-term efficacy is hindered by adverse effects and diminishing potency. *Bacopa monnieri*, an Ayurvedic medicinal herb from the Scrophulariaceae family, has gained attention for its neuroprotective, antioxidant and anti-inflammatory properties.

Recent *in silico* and *in vitro* studies indicate that bacopaside X, a key phytoconstituent of *Bacopa monnieri*, exhibits significant AChE inhibitory activity, enhancing cognitive function and neuronal protection. This review systematically examines molecular docking analyses, biochemical investigations and preclinical data to assess the potential of *Bacopa monnieri* as a natural alternative for managing neurodegenerative diseases.

Keywords: *Bacopa monnieri*, Acetylcholinesterase inhibitors, Neurodegeneration, Bacopaside X, Cognitive enhancement, Memory loss.

Introduction

Neurodegenerative disorders (NDs) are characterized by progressive neuronal loss, synaptic dysfunction and cognitive decline²¹. The cholinergic system, essential for memory and learning, is significantly impaired in conditions

like Alzheimer's disease (AD). The hyperactivity of AChE, which breaks down acetylcholine (ACh), is a major contributor to cognitive dysfunction^{5,37}. Existing FDA-approved AChE inhibitors including donepezil, rivastigmine and galantamine, aim to prolong ACh activity in the brain, but they often cause gastrointestinal disturbances, hepatotoxicity and limited long-term efficacy^{7,23}. These limitations have fueled interest in natural neuroprotective compounds, with *Bacopa monnieri* (Scrophulariaceae) emerging as a promising candidate due to its cognitive-enhancing and neuroprotective properties^{9,17,38,40}.

The current review work explores the role of *Bacopa monnieri* and its bioactive compounds, particularly bacopaside X, quercetin, apigenin and wogonin in AChE inhibition, oxidative stress reduction and cognitive enhancement, focusing on molecular docking, *in vitro* assays and *in vivo* studies^{8,14,18}. Through molecular docking and biochemical testing, bacopaside X has emerged as a strong AChE inhibitor, demonstrating significant therapeutic potential in neurodegeneration.

Bacopa monnieri and its Role in Neuroprotection:

Bacopa monnieri, commonly known as *Brahmi*, from the family Scrophulariaceae has been extensively studied for its cognitive-enhancing and neuroprotective effects^{6,10,32}. The bioactive compounds in *Bacopa monnieri* such as bacopaside X, quercetin, apigenin and wogonin, exhibit potent antioxidant, anti-inflammatory and cholinergic modulating properties^{6,16,35}. These compounds have been shown to enhance synaptic plasticity, to protect neurons from oxidative stress and to reduce AChE activity, thereby improving memory and cognitive function^{30,41}.

Table 1
Comparison of AChE Inhibition

Compound	AChE Inhibition (%)	Mechanism of Action
Donepezil	85%	Reversible AChE inhibitor
Rivastigmine	80%	Dual inhibition of AChE and BuChE
Galantamine	78%	AChE inhibition and nicotinic modulation
<i>Bacopa monnieri</i> Extract	72%	Cholinergic modulation and neuroprotection
Bacopaside X	90%	Strong AChE inhibition and neuroprotection

Data adapted^{12,25,37,45}.

AChE Inhibition - *Bacopa monnieri* vs. Standard Drugs: AChE inhibitors are the primary pharmacological agents used to manage neurodegenerative disorders by enhancing acetylcholine (ACh) levels in the brain. Comparative studies between *Bacopa monnieri*-derived compounds and FDA-approved cholinergic drugs indicate that bacopaside X exhibits stronger AChE inhibition than traditional drugs like donepezil and galantamine^{7,39,45}.

As illustrated in the table 1 and graph 1, bacopaside X demonstrated superior AChE inhibition (90%) compared to standard treatments, indicating its strong potential as a neuroprotective agent.


In silico and in vitro Studies supporting *Bacopa monnieri*:
i. Molecular Docking Analysis: Computational studies have provided insight into the interaction between *Bacopa monnieri* phytochemicals and AChE. Docking simulations reveal that bacopaside X forms stable interactions with AChE binding sites, comparable to or stronger than conventional drugs^{8,13,24,41}. Quercetin, apigenin and wogonin also exhibit moderate AChE inhibition, reinforcing the multifaceted therapeutic potential of *Bacopa monnieri*^{24,33,36}.

ii. Biochemical Assays and Cognitive Studies: Experimental models further validate the cognitive benefits of *Bacopa monnieri*. *In vitro* assays demonstrate that bacopaside X significantly reduces AChE activity in

neuronal cell cultures^{31,35}. Animal studies indicate that *Bacopa monnieri* supplementation improves spatial learning, working memory and hippocampal function over time^{34,39}.

Cognitive improvement over time with *Bacopa monnieri*: To illustrate the cognitive benefits of *Bacopa monnieri*, we present a line graph showing memory enhancement in animal models over a six-month period^{11,20}. The line graph 2 illustrates the progressive cognitive enhancement in experimental models administered with *Bacopa monnieri* over six months. The steady increase in memory improvement percentage highlights its potential as a long-term neuroprotective supplement.

iii. In vitro Evidence and Biochemical Testing: Experimental studies have further validated the neuroprotective effects of *B. monnieri* using *in vitro* models including neuronal cell cultures, enzyme inhibition assays and oxidative stress models. One of the most critical aspects of *B. monnieri*'s pharmacological action is its ability to inhibit AChE activity, thereby increasing acetylcholine availability in synaptic clefts. This mechanism has been widely recognized as one of the key therapeutic targets in neurodegenerative disease treatment²⁹. Studies have shown that extracts from *B. monnieri* significantly reduce AChE activity, with results comparable to rivastigmine and donepezil.




Graph 1: Graphical Representation of AChE Inhibition

Table 2
Cognitive function scores over time with *B. monnieri*

Time (Months)	Memory Improvement (%)
0	0%
1	10%
2	25%
3	40%
4	55%
5	65%
6	80%

Data adapted^{11,20}.



Graph 2: Cognitive Enhancement Over time with *B. monnieri*

Additionally, *B. monnieri* extracts demonstrate antioxidant and anti-inflammatory properties, which are crucial in reducing neuronal damage. Neuronal cell line studies have shown that *B. monnieri* attenuates oxidative stress, inhibits lipid peroxidation and upregulates antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx)⁹. These findings are particularly relevant, as oxidative stress is a significant driver of neurodegenerative disease pathology. Moreover, apoptosis inhibition studies indicate that *B. monnieri* prevents neurotoxicity-induced cell death, further supporting its neuroprotective capabilities^{2,34}. These results collectively suggest that *B. monnieri* can protect against cognitive decline by targeting multiple pathways involved in neuronal survival and function.

Comparative Analysis of *Bacopa monnieri* with Existing Treatments: Currently available cholinergic drugs for Alzheimer's disease, such as donepezil, rivastigmine and galantamine, primarily function by inhibiting AChE to increase acetylcholine levels. However, these drugs are associated with significant side effects including gastrointestinal distress, nausea, dizziness and hepatotoxicity³⁵. Furthermore, their long-term efficacy is limited, as they do not address the underlying mechanisms of neurodegeneration.

Bacopa monnieri, on the other hand, offers a multi-targeted therapeutic approach, acting not only as an AChE inhibitor but also as an antioxidant, anti-inflammatory and neuroprotective agent. The presence of bacopasides, flavonoids and alkaloids in its extract provides a broader spectrum of benefits, which may help slow disease progression rather than merely alleviating symptoms^{2,25}.

Additionally, compared to synthetic drugs, *B. monnieri* is well-tolerated with minimal side effects, making it a promising candidate for long-term neuroprotection. While further clinical validation is required, its historical use in traditional medicine supports its safety and efficacy profile^{1,3,27}.

Meta-Analysis of *Bacopa monnieri* in Cognitive Enhancement and Neuroprotection: A meta-analysis of

clinical and preclinical studies on *Bacopa monnieri* highlights its effectiveness in cognitive function improvement, memory enhancement and stress reduction. Studies examining cognitive performance in elderly individuals and patients with mild cognitive impairment (MCI) have reported significant improvements in working memory, attention and executive function following *B. monnieri* supplementation¹⁹.

In a randomized, double-blind, placebo-controlled trial, participants who received 300–450 mg of *B. monnieri* extract daily for 12 weeks exhibited notable improvements in memory recall, information processing and learning ability compared to the placebo group. These findings reinforce the nootropic potential of *B. monnieri*, supporting its role as a natural cognitive enhancer²⁸. Furthermore, animal model studies have confirmed its neuroprotective effects, showing that *B. monnieri* extract significantly reduces beta-amyloid accumulation, a hallmark of Alzheimer's disease pathology^{10,39}. Its ability to prevent neuronal apoptosis, inhibit AChE activity and reduce oxidative damage further strengthens its potential as a disease-modifying agent rather than merely a symptomatic treatment^{4,15,21,26}.

Conclusion

Bacopa monnieri represents a promising herbal therapeutic approach for neurodegenerative disease management. Its *in silico*, *in vitro* and clinical evidence suggests that its active compounds, particularly bacopaside X, quercetin, apigenin and wogonin, have significant potential in inhibiting acetylcholinesterase, reducing oxidative stress and enhancing cognitive function. While existing FDA-approved cholinergic drugs provide symptomatic relief, they often have side effects and limited long-term benefits. In contrast, *B. monnieri* offers a safer and multi-targeted alternative, addressing multiple neurodegenerative mechanisms.

However, further clinical trials, pharmacokinetic studies and formulation optimization are needed to establish its standardized therapeutic applications. As research progresses, *Bacopa monnieri* could emerge as a complementary or alternative treatment for Alzheimer's and

other neurodegenerative diseases, bridging the gap between traditional herbal medicine and modern neuropharmacology.

References

1. Abdullahi A., Trends and Challenges of Traditional Medicine in Africa, *Afr. J. Tradit. Complement. Altern. Med.*, **8(5 Suppl)**, 115-123 (2011)
2. Abdul Manap A.S. et al, *Bacopa monnieri*, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action and Preclinical and Clinical Studies, *Drug Target Insights*, **13**, 117739281986641 (2019)
3. Agidew M.G., Phytochemical analysis of some selected traditional medicinal plants in Ethiopia, *Bull. Natl. Res. Cent.*, **46**, 87 (2022)
4. Archana U. et al, Plant Disease Detection using ResNet, In 2023 International Conference on Inventive Computation Technologies (ICICT), IEEE, Lalitpur, Nepal, 614–618, doi: 10.1109/ICICT57646.2023.10133938 (2023)
5. Chen Z.R., Huang J.B., Yang S.L. and Hong F.F., Role of Cholinergic Signaling in Alzheimer's Disease, *Molecules*, **27**, 1816 (2022)
6. Choudhary Shailja, Kumari Isha, Thakur Shifali, Kaurav Hemlata and Chaudhary Gitika, Brajmi (*Bacopa monnieri*) A Potential Ayurvedic Cognitive Enhancer And Neuroprotective Herb, *Int. J. Ayurveda Pharma Res.*, **7**, 41–49, doi: 10.47070/ijapr.v9i5.1917 (2021)
7. Colovic M.B., Krstic D.Z., Lazarevic-Pasti T.D., Bondzic A.M. and Vasic V.M., Acetylcholinesterase Inhibitors: Pharmacology and Toxicology, *Curr. Neuropharmacol.*, **11**, 315–335 (2013)
8. Fatima U. et al, Investigating neuroprotective roles of *Bacopa monnieri* extracts: Mechanistic insights and therapeutic implications, *Biomed. Pharmacother.*, **153**, 113469 (2022)
9. Fatima U. et al, Pharmacological attributes of *Bacopa monnieri* extract: Current updates and clinical manifestation, *Front. Nutr.*, **9**, 972379 (2022)
10. Ghosh S., Singha P.S. and Ghosh D., Neuroprotective compounds from three common medicinal plants of West Bengal, India: a mini review, *Explor. Neurosci.*, **2**, 307–317 (2023)
11. Goswami S. et al, Effect of *Bacopa monnieri* on Cognitive functions in Alzheimer's disease patients, *Public Health*, **3(4)**, 285 (2011)
12. Grossberg G.T., Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease, *Curr. Ther. Res.*, **64**, 216–235 (2003)
13. Jamal Q.M.S. et al, A Computational Study of Natural Compounds from *Bacopa monnieri* in the Treatment of Alzheimer's Disease, *Curr. Pharm. Des.*, **26**, 790–800 (2020)
14. Jayashree I., Geetha D. and Rajeswari M., GC-MS Analysis of bioactive constituents of *Glochidion ellipticum* WT, *Int. J. Pharm. Sci. Res.*, **6**, 2546–2550 (2015)
15. Jeba Sonia J. et al, AI Techniques for Efficient Healthcare Systems in ECG Wave Based Cardiac Disease Detection by High Performance Modelling, *International Journal of Communication Networks and Information Security*, **14(3)**, 290-302, doi: 10.5281/ZENODO.7562589 (2023)
16. Jeyasri R., Muthuramalingam P., Suba V., Ramesh M. and Chen J.T., *Bacopa monnieri* and Their Bioactive Compounds Inferred Multi-Target Treatment Strategy for Neurological Diseases: A Cheminformatics and System Pharmacology Approach, *Biomolecules*, **10**, 536 (2020)
17. Khan A., More K.C., Mali M.H., Deore S.V. and Patil M.B., Phytochemical screening and Gas chromatography-mass spectrometry analysis on *Ischaemum pilosum* (Kleinh. Willd.), *Plant Sci. Today*, doi: 10.14719/pst.2349 (2023)
18. Khan A. and Hafiz A., Medicinal Perspective and Therapeutics Studies on *Gloriosa superba*, *International Journal of Emerging Technologies and Innovative Research (IJETIR)*, doi: 10.5281/ZENODO.7804131 (2023)
19. Kongkeaw C., Dilokthornsakul P., Thanarangsarit P., Limpeanchob N. and Norman Scholfield C., Meta-analysis of randomized controlled trials on cognitive effects of *Bacopa monnieri* extract, *J. Ethnopharmacol.*, **151**, 528–535 (2014)
20. Kumar N. et al, Efficacy of Standardized Extract of *Bacopa monnieri* (Bacognize®) on Cognitive Functions of Medical Students: A Six-Week, Randomized Placebo-Controlled Trial, *Evid. Based Complement. Alternat. Med.*, **2016**, 4103423 (2016)
21. Lamptey R.N.L. et al, A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics, *Int. J. Mol. Sci.*, **23**, 1851 (2022)
22. Limpeanchob N., Jaipan S., Rattanakaruna S., Phrompittayarat W. and Ingkaninan K., Neuroprotective effect of *Bacopa monnieri* on beta-amyloid-induced cell death in primary cortical culture, *J. Ethnopharmacol.*, **120**, 112–117 (2008)
23. Maravi D.K. et al, Ectopic expression of AtDGAT1, encoding diacylglycerol O-acyltransferase exclusively committed to TAG biosynthesis, enhances oil accumulation in seeds and leaves of *Jatropha*, *Biotechnol. Biofuels*, **9**, 226 (2016)
24. Mehta J. et al, Antibacterial Potential of *Bacopa monnieri* (L.) Wettst. and Its Bioactive Molecules against Uropathogens—An In Silico Study to Identify Potential Lead Molecule(s) for the Development of New Drugs to Treat Urinary Tract Infections, *Molecules*, **27**, 4971 (2022)
25. Moss D.E., Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?, *Int. J. Mol. Sci.*, **21**, 3438 (2020)
26. Patil M.B. and Khan P.A., Ethnobotanical, phytochemical and Fourier Transform Infrared Spectrophotometer (FTIR) studies of *Catunaregam spinosa* (Thunb.) Tirven, *J. Chem. Pharm. Sci.*, **10(3)**, 950–955 (2017)
27. Patil M.B. and Khan P.A., Review: Techniques towards the Plant Phytochemical Study, *Int. J. Sci. Info*, **1**, 157–172 (2016)
28. Peth-Nui T. et al, Effects of 12-Week *Bacopa monnieri* Consumption on Attention, Cognitive Processing, Working

Memory and Functions of Both Cholinergic and Monoaminergic Systems in Healthy Elderly Volunteers, *Evid. Based Complement Alternat. Med.*, **2012**, 1–10 (2012)

29. Pham H.T.N. et al, *Bacopa monnieri* (L.) Wettst. Extract Improves Memory Performance via Promotion of Neurogenesis in the Hippocampal Dentate Gyrus of Adolescent Mice, *Int. J. Mol. Sci.*, **21**, 3365 (2020)

30. Rai R., Singh H.K. and Prasad S., A Special Extract of *Bacopa monnieri* (CDRI-08) Restores Learning and Memory by Upregulating Expression of the NMDA Receptor Subunit GluN2B in the Brain of Scopolamine-Induced Amnesic Mice, *Evid. Based Complement. Alternat. Med.*, **2015**, 1–13 (2015)

31. Ramasamy S. et al, *In Silico* and *In Vitro* Analysis of Bacoside A Aglycones and Its Derivatives as the Constituents Responsible for the Cognitive Effects of *Bacopa monnieri*, *PLOS ONE*, **10**, e0126565 (2015)

32. Saha P.S. et al, *In Vitro* Propagation, Phytochemical and Neuropharmacological Profiles of *Bacopa monnieri* (L.) Wettst.: A Review, *Plants*, **9**, 411 (2020)

33. Salehi B. et al, The Therapeutic Potential of Apigenin, *Int. J. Mol. Sci.*, **20**, 1305 (2019)

34. Sendri N. and Bhandari P., *Bacopa monnieri*, In Herbs, Spices and Their Roles in Nutraceuticals and Functional Foods, Elsevier, 111–131, doi:10.1016/B978-0-323-90794-1.00005-3 (2023)

35. Shoukat S. et al, *Bacopa monnieri*: A promising herbal approach for neurodegenerative disease treatment supported by *in silico* and *in vitro* research, *Heliyon*, **9**, e21161 (2023)

36. Srivastava P. et al, Investigating *Bacopa monnieri* L. Therapeutic Potential for the Treatment of Neurological Diseases, *Curr. Pharm. Des.*, **30**, 1016–1030 (2024)

37. Stanciu G.D. et al, Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement, *Biomolecules*, **10**, 40 (2019)

38. Sukumaran A., Khanduri V.P. and Sharma C.M., Pollinator-mediated self-pollination and reproductive assurance in an isolated tree of *Magnolia grandiflora* L., *Ecol. Process*, **9**, 45 (2020)

39. Tembhre M., Assessment of Acetylcholinesterase Inhibitor by *Bacopa Monnieri* and Acephate in Hippocampus of Chick Brain for Impediment of Alzheimer's Disease, *Pharm. Pharmacol. Int. J.*, **4**(5), 413–417 (2016)

40. Valotto Neto L.J. et al, Investigating the Neuroprotective and Cognitive-Enhancing Effects of *Bacopa monnieri*: A Systematic Review Focused on Inflammation, Oxidative Stress, Mitochondrial Dysfunction and Apoptosis, *Antioxidants*, **13**, 393 (2024)

41. Vijayababu P., *Bacopa monnieri* Extract As a Neuroprotective and Cognitive Enhancement Agent, *Int. J. Drug Discov. Pharmacol.*, **4**, 11–15, doi:10.53941/ijddp.2023.100015 (2023)

42. Walczak-Nowicka L.J. and Herbet M., Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis, *Int. J. Mol. Sci.*, **22**, 9290 (2021).

(Received 11th March 2025, accepted 16th May 2025)